Evidence map›Paper›PMID 34171421›Full record

ReviewGastroenterologia y hepatologia2022

Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.

Carles Suria, Marta M Bosca-Watts, Pablo Navarro, Joan Tosca, Rosario Anton, Ana Sanahuja, Marta Revaliente, Miguel Minguez

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterologia y hepatologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Carles SuriaDigestive Disease Department, University of Valencia, Clinic University Hospital of Valencia, Valencia 46010, Spain. Electronic address: carles_71191@hotmail.com.
Marta M Bosca-WattsDigestive Disease Department, University of Valencia, Clinic University Hospital of Valencia, Valencia 46010, Spain.
Pablo NavarroDigestive Disease Department, University of Valencia, Clinic University Hospital of Valencia, Valencia 46010, Spain.
Joan ToscaDigestive Disease Department, University of Valencia, Clinic University Hospital of Valencia, Valencia 46010, Spain.
Rosario AntonDigestive Disease Department, University of Valencia, Clinic University Hospital of Valencia, Valencia 46010, Spain.
Ana SanahujaDigestive Disease Department, University of Valencia, Clinic University Hospital of Valencia, Valencia 46010, Spain.
Marta RevalienteDigestive Disease Department, University of Valencia, Clinic University Hospital of Valencia, Valencia 46010, Spain.
Miguel MinguezDigestive Disease Department, University of Valencia, Clinic University Hospital of Valencia, Valencia 46010, Spain.
Universitat de València · ESHospital Clínico Universitario de Valencia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has been a challenge for countries and health professionals worldwide. Viral entry by ACE-2 receptor and an excessive activation of the immune system are key to understand both incidence and severity of disease. Inflammatory Bowel Disease (IBD) represents a special condition associated with an inordinate response of the immune system to external agents. IBD treatments have been associated to an increased risk of bacterial and viral infections. This has raised the question of possible higher incidence and severity of COVID-19 infection in IBD patients. Several papers have been published during this year of pandemic to answer that question. Moreover, COVID-19 vaccination offers great promise in controlling infection in patients with IBD. Based on current evidence, patients with IBD do not have a higher incidence of COVID-19 than the general population, and they do not have worse disease evolution. Advanced age and presence of a greater number of comorbidities have been associated with worse outcomes, similar to the general population. Corticosteroids are associated to an increased risk of COVID-19 infection, higher hospitalization rate and higher risk of severe COVID-19. 5-ASA/Sulfasalazine and Thiopurines have a possible increased risk of severe COVID-19, although studies are lacking. On the other hand, Anti-TNF may have a possible protective effect. It is recommended to maintain the treatment. Anti-IL-12/23, anti-integrins and tofacitinib have results comparable to anti-TNF. Based on the efficacy, expert recommendations, and the absence of other evidence, it is recommended that patients with IBD be vaccinated.

Indexed as

COVID-19Inflammatory Bowel DiseasesCOVID-19 VaccinesHumansPandemicsTumor Necrosis Factor InhibitorsCOVID-19 VaccinesTumor Necrosis Factor InhibitorsCOVID-19 graveCOVID-19 incidenceCOVID-19 vaccineEnfermedad inflamatoria intestinal (EII)IBD-treatmentIncidencia por COVID-19Inflammatory Bowel Disease (IBD)Severe COVID-19tratamiento de la EIIVacuna COVID-19

Identifiers

PMID34171421
PMCPMC8219948
OpenAlexW3174077496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.